KD Logo

Understanding the Risks of Investing in Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals plc’s recent filing unveils that its SVP, Chief Accounting Officer Carr Patricia unloaded Company’s shares for reported $17738.0 on Jun 07 ’24. In the deal valued at $108.83 per share,163 shares were sold. As a result of this transaction, Carr Patricia now holds 6,596 shares worth roughly $0.69 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, Patil Neena M sold 5,000 shares, generating $548,250 in total proceeds. Upon selling the shares at $109.65, the EVP & Chief Legal Officer now owns 36,629 shares.

Before that, Carr Patricia sold 1,768 shares. Jazz Pharmaceuticals plc shares valued at $206,821 were divested by the SVP, Chief Accounting Officer at a price of $116.98 per share. As a result of the transaction, Carr Patricia now holds 6,596 shares, worth roughly $0.69 million.

Goldman initiated its Jazz Pharmaceuticals plc [JAZZ] rating to a Buy in a research note published on June 05, 2024; the price target was $169. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. UBS also remained covering JAZZ and has decreased its forecast on November 27, 2023 with a “Neutral” recommendation from previously “Buy” rating. Raymond James started covering the stock on September 29, 2023. It rated JAZZ as “a Mkt perform”.

Price Performance Review of JAZZ

On Tuesday, Jazz Pharmaceuticals plc [NASDAQ:JAZZ] saw its stock fall -1.30% to $105.09. Over the last five days, the stock has lost -2.77%. Jazz Pharmaceuticals plc shares have fallen nearly -14.56% since the year began. Nevertheless, the stocks have fallen -15.23% over the past one year. While a 52-week high of $146.70 was reached on 02/26/24, a 52-week low of $103.01 was recorded on 05/02/24. SMA at 50 days reached $108.79, while 200 days put it at $119.62. A total of 0.4 million shares were traded, compared to the trading of 0.39 million shares in the previous session.

Levels Of Support And Resistance For JAZZ Stock

The 24-hour chart illustrates a support level at 104.20, which if violated will result in even more drops to 103.32. On the upside, there is a resistance level at 106.25. A further resistance level may holdings at 107.42. The Relative Strength Index (RSI) on the 14-day chart is 40.51, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.16, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.33%. Stochastics%K at 7.96% indicates the stock is a buying.

Most Popular